This trial is evaluating whether Repotrectinib will improve 2 primary outcomes in patients with Cancer, Advanced. Measurement will happen over the course of 8 weeks following the start of treatment.
This trial requires 50 total participants across 1 different treatment group
This trial involves a single treatment. Repotrectinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"The most accepted theory today for cancer cause is the “tut” or "taboo" of a demon who destroys mankind at some point in the past. But that isn't true for most people. According to the World Health Organization's latest data, cancer, in 2015, was the cause of 7.7 million deaths worldwide, up from 2.4 million in 1990. And worldwide cancer death rates have dropped from 2.1 million in 1990 and 7.4 million in 2000. According to one study, “tobacco, alcohol, obesity, UV rays, and diet are just a few factors that have been shown to be highly associated with some cancers." - Anonymous Online Contributor
"The use of cancer treatment based on the theory that this disease is a deficiency of vitamin B17 is not justified and is based on quackery." - Anonymous Online Contributor
"This article discusses the various entities, aspects and perspectives on cancer and its differentiating characteristics. It starts with a short description of cancer and its various subtypes and continues with defining cancer from a molecular/systems perspective, which also illustrates how cancer evolves by combining various tumor-host interactions." - Anonymous Online Contributor
"Most cancers are asymptomatic, i.e. symptom-free. Symptoms may arise as a result of increased intrathoracic pressure on the brain from primary tumour growth, metastasis or secondary tumours, or as a result of the spread of cancer tumour or metastases." - Anonymous Online Contributor
"A minority of common cancer treatments are used by > 50% of patients with different types of cancer. However, the majority of patients with each specific cancer type are prescribed a common cancer treatment. Recent findings may reflect common treatments in clinical practice, provider preferences, and limitations in health information retrieval. Clin Cancer Res;22(16); 3990-4001. ©2016 AACR." - Anonymous Online Contributor
"At the time of diagnosis, it is estimated that 940,000 people develop cancer annually and 780,000 die of cancer. A year after cancer diagnosis, the number of people diagnosed with cancer continues to rise at a rate of 6.6%, but the number of people still living a full life year after cancer diagnosis (that is, cancer-free) continues to decrease at a rate of 3.1%. This means that in a year, more people die in the United States than is diagnosed with cancer; however, our data do not reflect the full burden of cancer because individuals who die without ever knowing of cancer receive zero cancer-specific survivorship." - Anonymous Online Contributor
"The average age of diagnosis for cancer is 66.7 years, and the average age of death is 71.6 years. The overall survival rate is 68.2% and the mortality rate is 12.7%. This is consistent with the average life span, since the average age of death for the Netherlands is 79.3 years and the average life span is about 81.7 years." - Anonymous Online Contributor
"The most recent data from studies using current or previous repotrectinib in advanced cancer are shown in Table 6. Note that none of these studies is comparing repotrectinib to standard cytotoxic chemotherapy.\n\n- "" - Anonymous Online Contributor
"Cancer is deadly, it can kill fast, and it can kill young – even when detected early thanks to modern treatment methods. The only way is to get the cancer cured. And even when it is cured, the risks of recurrence and reoccurrence, of regrowth and re-regrowth must be faced." - Anonymous Online Contributor
"The familial risk for cancers is higher for cancers with higher genetic heterogeneity. This suggests that for certain types of cancer, a better understanding of their etiology may involve consideration of genetic heterogeneity as measured by the clustering of specific cancer genes or genetic markers in families as well as other forms of population genetic analyses." - Anonymous Online Contributor
"The use of repotrectinib resulted in an improvement in the QoL of people with cancer. The use of repotrectinib for those with non-small cell lung cancer resulted in an improvement in the QoL score of those with both advanced and metastatic non-small cell lung cancer." - Anonymous Online Contributor
"There were two phase I trials. The more recent is being conducted at the same site. There were no results available as of yet to show which side effects there would be, which dose and duration, or the safety of the drug. A second trial is under way to determine the antitumor activity of the compound. No results as of May 2016. This drug is being developed by Aptus Therapeutics, a biotechnology company based in Cambridge, UK, which uses its technology to identify and evaluate potential medicines with therapeutic action in a wide range of disease states." - Anonymous Online Contributor